Lymph Nodes News and Research

RSS

Exploring the systemic infection of SARS-CoV-2 in a wild leopard in India

A new study focused on the pathomorphological and virological characterization of SARS-CoV-2 in naturally infected, wild Indian Leopard.

17 Jan 2022

Naïve T cells suggested as critical to low mortality of children with COVID-19

A new study discusses how naïve T cells may contribute to lower mortality rates seen in children with COVID-19.

14 Jan 2022

Study advances the understanding of lymphatic vessels serving the heart

Scientists at the UNC School of Medicine led a study to advance the understanding of lymphatic vessels, which transport lymph, a clear fluid containing important molecules, immune cells and fluid, away from organs and tissues and back to the bloodstream.

13 Jan 2022

Nanovaccines and their immunomodulatory effect against human viruses

A review ]presented the primary progress of nanovaccines against the main viral illnesses.

13 Jan 2022

Using lab-grown stomachs to shed light on the symptoms of COVID-19

Could lab-grown 'mini-stomachs' be used to look at COVID-19 symptoms in children? In this interview, we speak to Paolo De Coppi to find out more.

13 Jan 2022

High SARS-CoV-2 seroprevalence among captive white-tailed deer in Texas

Researchers investigate the SARS-CoV-2 exposure and infection status of captive white-tailed deer in Texas.

12 Jan 2022

Novel mechanisms controlling tertiary lymphoid structure formation in tumors revealed

Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures.

11 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

Scientists unravel how LPS prevents or promotes development of allergic disease

Immunologists have long been baffled by LPS, the bacterial lipopolysaccharide that helps form the cell walls of Gram-negative bacteria.

5 Jan 2022

Study helps explain why mRNA vaccines have been successful at preventing severe COVID-19

Washington University in St. Louis student Julian McCall receives a dose of Pfizer's mRNA-based COVID-19 vaccine.

24 Dec 2021

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

A recent review article discusses recent advances in protein-based nanoparticle vaccines against SARS-CoV-2.

22 Dec 2021

Understanding SARS-CoV-2-induced systemic amyloidosis

A new study proposed that inflammation combined with aggregates of amyloidogenic peptides of SARS-CoV-2 S proteins might induce systemic amyloidosis.

21 Dec 2021

Lung memory B-cells provide primary protection against SARS-CoV-2 reinfection

Researchers study influenza and SARS-CoV-2 infection models to identify lung memory B cells during viral infection.

20 Dec 2021

White-tailed deer are efficient carriers of SARS-CoV-2

Researchers demonstrate the susceptibility of white-tailed deer to SARS-CoV-2.

20 Dec 2021

University of Birmingham launches 5 new major studies focused on management of type 1 diabetes

The University of Birmingham today announces the launch of five new major studies aimed at improving the prevention, treatment and management of type 1 diabetes – with a particular focus on children and young adults.

17 Dec 2021

Primary responses to SARS-CoV-2 in COVID-19 naïve vaccinees

Researchers evaluated primary responses in SARS-CoV-2-naïve vaccinees, as well as secondary responses in the SARS-CoV-2-infected vaccines, and observed a clear set of differences in their clinical symptoms, antibody levels, and cellular and mucosal immune responses.

17 Dec 2021